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Abstract The idiotypes of B cell lymphomas represent
tumor-speciﬁc antigens. T cell responses induced by idio-
type vaccination in vivo are directed predominantly against
CDR peptides, whereas in vitro T cells also recognize
framework-derivedepitopes.Toinvestigatethemechanisms
regulatingthespeciﬁcityofidiotype-speciﬁcTcells,BALB/
c or B10.D2 mice were immunized with mature dendritic
cells loaded with H-2K
d-restricted peptides from inﬂuenza
hemagglutinin, or from shared (J region) or unique (CDR3)
structures of the A20 lymphoma idiotype. Antigen-speciﬁc
T cells were induced in vivo by the CDR3 and inﬂuenza
epitopes, but not by the J peptide. Gene expression proﬁling
of splenic regulatory T cells revealed vaccination-induced
Treg activation and proliferation. Treg activity involved J
epitope-dependent IL-10 secretion and functional suppres-
sion of peptide-speciﬁc effector T cells. Vaccination-induced
in vivo proliferation of transgenic hemagglutinin-speciﬁc T
cells was suppressed by co-immunization with the J peptide
and was restored in CD25-depleted animals. In conclusion,
Treg induced by a shared idiotype epitope can systemically
suppress T cell responses against idiotype-derived and
immunodominant foreign epitopes in vivo. The results
imply that tumor vaccines should avoid epitopes expressed
by normal cells in the draining lymph node to achieve
optimal anti-tumor efﬁcacy.
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Introduction
Immunoglobulins contain unique primary sequences that
are created by Ig gene rearrangement and may be diversi-
ﬁed further by somatic hypermutation. The individual
composition of immunogenic epitopes within the variable
region of a given immunoglobulin is designated as ‘‘idio-
type’’ (Id). Since the Id is an unique feature of the
respective B cell clone, it represents an individual tumor-
speciﬁc antigen of malignant B cell lymphomas [1].
Immunization of patients with indolent B cell lymphomas
against their lymphoma-derived Id induces speciﬁc
immune responses [2–6]. In patients immunized during
clinical remission, induction of anti-Id antibodies is cor-
related with a favorable outcome [7, 8]. The role of Id-
speciﬁc T cells for efﬁcacious anti-lymphoma immunity is
less clear.
In animal models, MHC class II-restricted T cells with
speciﬁcity for hypermutated Id-derived epitopes exert
immunosurveillance against the corresponding malignant B
cell clone [9]. Augmentation of cellular anti-Id immunity
by active immunization may also prevent tumor progres-
sion in experimental lymphoma models [9–11]. In contrast,
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123the murine T cell repertoire is generally tolerant to germ
line-encoded immunoglobulin sequences and may also be
actively tolerized to individual Id epitopes [12].
We have previously described Id-speciﬁc, MHC class I-
restricted cytotoxic T cells in lymphoma-bearing patients
[13]. More recently, a reverse immunology bioinformatics
study has indicated MHC class I-dependent immunosur-
veillance against individual CDRs of the Ids in human
follicular lymphoma patients [14]. In accordance with the
murine models, Id vaccination of patients induces in vivo
preferentially T cells with speciﬁcity for CDR peptides or
hypermutated epitopes [3, 15, 16]. In order to investigate
the mechanisms governing the speciﬁcity of vaccination-
induced T cell immunity to Id in a wild-type immune
repertoire, we performed comparative immunizations with
a highly individual CDR3 epitope and a conserved FR
epitope in a murine lymphoma model. A highly immuno-
genic inﬂuenza HA peptide [17] served as a reference
standard for the analysis of immunization-induced T
effector populations.
Materials and methods
Immunization
1 9 10
6 DC matured and activated under serum-free con-
ditions [18] were loaded with H-2k
d-restricted peptides
(Proimmune, Oxford, UK) and injected into the hind paw
of BALB/c or B10.D2 mice. For in vivo depletion of
Treg, 500 lg of anti-CD25 Ab PC61 (ATCC, Manassas,
VA, USA) was injected i.p. 3 days prior to immunization.
All in vivo experiments were performed at least three
times.
In vivo assays
Ag-speciﬁc T cells were analyzed 1 week after immuni-
zation by ﬂow cytometry with ﬂuorochrome-labeled Ab
(BD Biosciences or eBioscience, both in San Diego, CA,
USA) and peptide-H-2K
d multimers (Proimmune).
For in vivo detection of speciﬁc cytotoxicity, spleno-
cytes were pulsed with 10 lg/ml antigenic or control
peptide for 1 h at 37C and labeled for 10 min separately
with 0.5 or 5 lM CFSE, respectively. 1 9 10
7 cells of each
population were mixed and injected i.v. into recipient mice.
After 24 h, peripheral blood was analyzed by ﬂow
cytometry.
To measure vaccination-induced T cell proliferation,
1 9 10
6 CD8
? (CD8 isolation kit, Miltenyi Biotech, Berg-
isch-Gladbach, Germany), CFSE-labeled (5 lM) clone 4
cells were injected i.v. into congenic CD45.2
? mice 3 days
after immunization. Clone 4Tcells (kindly providedby D.J.
Morgan, University of Bristol) express a transgenic TCR
with speciﬁcity for an immunodominant HA peptide [19].
4 days after adoptive transfer, CD8
?CD45.1
?CD45.2
-,
H-2K
d-multimer-positive splenocytes were analyzed for
CFSE dilution.
Intracellular staining for IFN-c
Effector cells were incubated for 5–16 h in the presence of
10 lM peptide and 1 ll/ml GolgiStop (BD Biosciences). In
restimulation experiments, H-2K
d T2 cells (kind gift of
S. Stevanovic, Tu ¨bingen, Germany) pulsed for 24 h with
10 lM peptide were added as stimulators. After staining of
cellular surface antigens, cells were ﬁxed with 2% form-
aldehyde and stained in 0.5% saponin with XMG2 anti-
IFN-c Ab (BD Biosciences).
In vitro restimulation of Ag-speciﬁc T cells
Splenocytes were cultured in FCS-supplemented RPMI
medium with 10 lg/ml peptide. After 2 days, viable cells
were recovered by Ficoll gradient centrifugation and cul-
tured in medium supplemented with 50 U/ml rIL-2 (Pep-
rotech, Rocky Hill, NJ, USA). Cells were analyzed after
7–9 days of restimulation.
Fig. 1 Speciﬁc T cell responses after DC-based peptide immuniza-
tion. a Representative measurement of peptide-speciﬁc T cells with
gating on CD8
? cells and subtraction of controls with irrelevant
multimer or peptide. Upper panel draining LN. Middle panel
intracellular IFN-c production of splenocytes after overnight incuba-
tion with peptide. Lower panel intracellular IFN-c production of
splenocytes after peptide restimulation for 8 days and subsequent
incubation with peptide-pulsed T2-K
d cells. b Recognition of the
native CDR3 peptide (CDR3
nat) after immunization with heteroclitic
CDR3 peptide (CDR3
het) as detected by ELISpot. Background spots
with the respective irrelevant peptide (HA for CDR3 and J peptides;
CDR3
het for HA) were subtracted. c Measurement of peptide binding
to H-2K
d. After incubation of T2-K
d cells with the indicated peptides
for 24 h, surface expression of H-2K
d was quantitated by ﬂow
cytometry. The MFI of unpulsed cells was subtracted. MFI mean
ﬂuorescence intensity. d In vivo cytotoxicity with peptide-loaded,
CFSE-labeled splenocytes in the peripheral blood after immunization
with the indicated peptides. Right panel summary of in vivo
cytotoxicity in experimental groups. e In vitro cytotoxicity against
peptide-loaded, CFSE-labeled T2 cells after restimulation of spleno-
cytes for 8 days. PI
? cells were measured within the CFSE
?
population. J? J-induced effectors, J-pulsed T2; J- J-induced
effectors, CDR3-pulsed T2; CDR3? CDR3-induced effectors,
CDR3-pulsed T2; CDR3- CDR3-induced effectors, J-pulsed T2.
f Ag-speciﬁc splenocytes after immunization with HA or modiﬁed J
peptide (J
mut). g In vivo cytotoxicity against peptide-loaded, CFSE-
labeled splenocytes in the peripheral blood after peptide immuniza-
tion. Symbols represent individual animals
b
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123In vitro cytotoxicity assay
T2 cells were pulsed with 10 lg/ml peptide overnight and
stained with 5 lM CFSE. 10
4 target cells were incubated
with effector T cells in different E:T ratios for 4 h. Cyto-
toxicity was determined by ﬂow cytometry as the CFSE
?/
propidium iodide
? cell fraction.
Isolation and IL-10 production of CD4
?CD25
? Treg
CD4
?CD25
? T cells were isolated from LN or spleen by
depletion of non-CD4
? cells and subsequent positive
selection of CD25
? cells (Regulatory T Cell Isolation Kit;
Miltenyi). After 2 days of coculture of 1 9 10
6 cells of the
CD4
- fraction with isolated CD4
?CD25
? cells, the IL-10
concentration in the culture supernatant was determined by
ELISA (BD Biosciences).
Gene expression proﬁling of Treg
10 lg of biotin-labeled and fragmented cRNA (MessageA-
mpTM II-Biotin Enhanced kit, Ambion AM1791) of
splenic CD4
?CD25
?IL7R
- Treg [20] were hybridized to
GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix,
Santa Clara, CA, USA) at 45C for 16 h. The arrays were
washed (FS450_0004 protocol, Fluidics Station FS450,
Affymetrix), scanned (GeneChip 3000 7G Scanner, Af-
fymetrix), and converted into CEL ﬁles (GeneChip
Command Console Software Version 1.0, Affymetrix).
CEL ﬁles were imported into the Reﬁner module of
Expressionist software 5.1.2 (Genedata, Basel, Switzer-
land), where RMA background subtraction, quantile nor-
malization, and probe summarization with the median
polish activity were performed using the Bioconductor
RMA condensing algorithm [21]. Data were then imported
into the Analyst module of Expressionist and further nor-
malized by median scaling to an expression value of 200
over all probe sets except the bacterial spike probes. Dif-
ferentially expressed genes were identiﬁed with an
unpaired Bayes T test (CyberT) with Bayes Conﬁdence
Estimate Value set to 10 and a window size of 101 genes
[22]. False-discovery rates were estimated by the method
of Benjamini and Hochberg [23]. Median expression ratios
between Treg and Tconv were calculated for individual
genes by the ‘N-fold regulation’-activity of Analyst. Over-
or underrepresentation of certain gene ontologies within
selected gene lists in Analyst was identiﬁed by Fisher’s
exact test with a p value threshold of 0.001 and a property
size threshold of 10.
Analysis of TCR repertoires
cDNA was synthesized (Superscript II reverse transcrip-
tase; Invitrogen, Carlsbad, CA, USA) from RNA isolated
from CD4
?CD25
? splenocytes 1 week after vaccination
(RNeasy Kit; Qiagen, Hilden, Germany). 2 ll of cDNA
were ampliﬁed by PCR with 1 lM V and C primers and
0.1 U/llo fTaq polymerase (Qiagen) with an annealing
temperature of 60C[ 24]. PCR products were labeled with
6-FAM-labeled 30 C primer and PFU polymerase (Strata-
gene) for three cycles using an annealing temperature of
60C. Denatured labeled PCR products (1.3 ll) were ana-
lyzed on an Prism 3110 XL Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) with GeneScan 500
LIZ size standard and Genemapper 4.0 software 4.0
(Applied Biosystems).
Results
CDR3- but not J region-speciﬁc T cells are induced
in vivo by DC immunization
We identiﬁed a H-2K
d-restricted CDR3 peptide (YYC
SISGDY) from the published A20 IgH sequence [25]b y
theBIMASalgorithm(http://www-bimas.cit.nih.gov/molbio/
hla_bind/).Thispeptidehasnosigniﬁcantproteinhomologies
as determined by BLAST search. The A20 J peptide DY-
WGQGTEL [26] contains two amino acids that are assigned
to the CDR3 region. However, these residues are non-poly-
morphic, and a BLAST search of the J peptide yielded
Fig. 2 Gene expression proﬁling of Treg after DC-based peptide
immunization. a Isolation of CD4
?CD25
?IL7R
- Treg and
CD4
?CD25
-IL7R
? splenocytes by ﬂow cytometry. b Analysis of
immunization-dependent changes in the Treg transcriptome. Left
upper plot correlation of the common Treg signature [28]( x axis)
with expression ratios of splenic naive Treg and Tconv in this study
(y axis). Left lower plot comparison of induced changes in the
common Treg signature under different stimulation conditions.
A Treg stimulation index was calculated for every gene of the
common Treg signature by dividing the expression ratio of stimulated
Treg/stimulated Tconv through the expression ratio of naive Treg/
naive Tconv. x axis Treg stimulation index derived from direct in
vitro stimulation of TCR transgenic T cells with the cognate Ag [28].
y axis Treg stimulation index derived from splenocytes after in vivo
DC-based immunization of wild-type mice with MHC class I-
restricted peptide epitopes. Right panel inﬂuence of DC-based
immunization on the global Treg transcriptome depicted by fold
change versus fold change (FcFc) plot of expression ratios between
Treg and Tconv from spleens of naive (x axis) and DC-immunized
(y axis) mice. Blue dots indicate genes of the common Treg signature
[28] Red dots indicate genes of a Treg activation signature deﬁned by
[/\ twofold, highly signiﬁcant (q\0.01) immunization-induced
expression difference in Treg and absence of a major expression
difference (0.75–1.25fold change) in Tconv. c Expression of Ki67 and
Ly6a in Treg and Tconv from various anatomical locations after J
peptide immunization. d Summary of expression (mean and SEM) of
selected proteins in Treg and Tconv. Non-immunized: n = 2 animals.
Immunized: n = 6 animals (2 mice J immunized, 4 mice CDR3-
immunized)
b
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123hundreds of matches with murine IgH sequences (data not
shown).
Single immunization of mice with DC loaded with the
HA peptide IYSTVASSL [17] efﬁciently induced speciﬁc
effector T cells (Fig. 1a). Immunization with a heteroclitic
version [27] of the CDR3 peptide (CDR3
het, YYCSISGDL)
induced Ag-speciﬁc T cells that also recognized the native
CDR3 peptide (Fig. 1b). Immunization with the J peptide
failed to induce a detectable T cell response (Fig. 1a).
Since the J peptide effected the highest H-2K
d stabilization
in a T2 binding assay, the differential immunogenicity of
the peptides was not attributable to MHC binding (Fig. 1c).
Peptide-pulsed target cells were eliminated in vivo in HA-
and CDR3-immunized but not in J-immunized animals
(Fig. 1d). In contrast, in vitro restimulation expanded Ag-
speciﬁc T cells with strong speciﬁc cytotoxicity from all
three immunization groups (Fig. 1a, e).
To explore how dependent the lack of J peptide in vivo
immunogenicity was on its precise amino acid sequence,
we immunized mice with a mutated J peptide (J
mut;
DYWEQTEL). This minor modiﬁcation resulted in high
frequencies of peptide-speciﬁc splenocytes (Fig. 1f) and
moderate but robust in vivo cytotoxicity of J
mut-induced
effectors (Fig. 1g).
DC-based peptide J immunization induces Treg activity
in vivo
Since the discrepancy between in vivo and in vitro cyto-
toxicity after J immunization suggested Treg as a potential
suppressor mechanism of J-speciﬁc T cells in vivo, we
performed gene expression proﬁling of splenic
CD4
?CD25
?IL7R
- Treg [20] (Fig. 2a). The Treg pheno-
type was validated by the expression of Il2ra (CD25),
FoxP3, Tnfrsf18 (GITR), and Ctla4 (Supplemental
Table 1). Expression of the 603 genes of the so-called
‘‘common Treg signature’’ [28] correlated with published
data in naive mice (r = 0.68, p\0.0001; Supplemental
Table 2). This signature was also stable after DC-based
immunization (r = 0.82, p\10
-15; blue dots in Fig. 2b).
The Treg-speciﬁc expression of genes linked to Treg
function (annotated in Fig. 2b) was better preserved after
DC-based immunization in vivo than published for direct
TCR-mediated Treg stimulation in vitro [28].
A reaction of splenic Treg to DC-based immunization
was indicated by signiﬁcant (q\0.01; p = 2.2 9 10
-7–
2.4 9 10
-14), at least twofold transcriptional change in
1,266 genes (1,098 up- and 168 downregulated). Immuni-
zation-induced transcriptional regulation of 300 of these
1,266 genes was restricted to Treg as indicated by an
expression ratio of 0.75–1.25 between splenic conventional
T cells (Tconv) from immunized and naive mice (red dots
in Fig. 2b). Only 6 of these 300 genes (2%) were members
of the common Treg signature, and only two genes
(Dock10, Wnk1) were known FoxP3 target genes [29].
However, these 300 genes included the upregulated Treg
effector cytokine TGF-beta [30], and testing for enriched
gene ontology groups identiﬁed post-translational protein
modiﬁcation by phosphatase activity (Ppp1cb, Sbf1,
Ptp4a3, Ppp5c), gene silencing by methylation (Dnmt3a,
Eif2c2, Eif2c3, Adar, Dnmt1), and inhibition of translation
initiation (Eif4ebp2, Eif4ebp3) as processes that were
signiﬁcantly enhanced (Supplemental Table 3).
The transcriptional upregulation of Ly6a in splenic Treg
wasveriﬁedincomparisontotheTregsurfacemarkersCD25
and folate receptor 4 [31]b yﬂ o wc y t o m e t r yf o rT c o n va n d
FoxP3
? Treg from various anatomical locations (Fig. 2c, d).
Vaccination-induced changes of these markers were most
pronounced in the draining LN. Intracellular expression of
Ki67, which was upregulated 2.05-fold in splenic Treg after
vaccination (p = 3.12 9 10
-6, q = 0.13), indicated a pro-
liferative response of Treg to DC-based immunization that
was higher in the draining LN than in the spleen (Fig. 2c, d).
However, even in the draining LN, we were unable to detect
any signiﬁcant differences between J- or CDR3-immunized
mice with respect to phenotype (not shown) or total numbers
of CD4
?CD25
?FoxP3
? Treg (Fig. 3a).
Induction of Treg suppressive function by J peptide
immunization
After J immunization, FoxP3
? Treg from the draining LN
proliferated spontaneously in vitro (Fig. 3b). In cocultures
of CD4
?CD25
? T cells with CD4
- T cells, substantial
Fig. 3 Functional analyses of Treg after DC-based peptide immuni-
zation. a Proportion of CD4
?FoxP3
? cells of total cells (left panels)
and CD25
?FoxP3
? cells within the CD4
? population (right panels)
in the draining LN. b Spontaneous in vitro proliferation of isolated
CD4
?CD25
?, CFSE-labeled LN cells from J- or CDR3-immunized
mice during 1 week of culture in the presence or absence of the CD4
-
cell fraction of the same LN. Histograms depict gated CD4
?FoxP3
?
cells as indicated by rectangles in corresponding contour plots.
c Secretion of IL-10 (mean and SEM) by CD4
?CD25
? cells as
detected by ELISA. Triplicates of CD4
- splenocytes from either J- or
CDR3-immunized mice were cultured with the vaccine peptide
together with CD4
?CD25
? splenocytes from the same animals. d Ag-
dependent IL-10 secretion (mean and SEM) by immunization-induced
Treg as detected by ELISA. Triplicates of CD4
- splenocytes from J-
or CDR3- immunized mice were cultured with the vaccine peptide
with or without addition of 8% CD4
?CD25
? Treg from J- or CDR3-
immunized mice. e Inhibition of CDR3-speciﬁc effector cells by
CDR3- or J-induced Treg in vitro. CD4
- splenocytes from CDR3-
immunized mice were restimulated for 1 week with CDR3 peptide
together with isolated subpopulations of splenocytes from CDR3- or
J-immunized mice as indicated. CDR3-speciﬁc effector cells were
measured with CDR3 peptide/H-2K
d multimer complexes and anti-
CD62L in the CD8
? population by ﬂow cytometry. Reconstituted
cells comprise mixture of CD4
-, CD4
?CD25
-, and CD4
?CD25
?
cells from CDR3-immunized spleens according to their natural
composition
b
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123amounts of IL-10 were detected after J immunization
depending on the cellular proportion (Fig. 3c) and indepen-
dent of the effector T cell speciﬁcity (Fig. 3d). CD4
?CD25
?
Treg from J-immunized animals suppressed peptide-induced
in vitro expansion of CDR3-speciﬁc CD8
? splenocytes
stronger than CDR3-induced cells (Fig. 3e).
J peptide-induced Treg suppress T cell responses to HA
at different stages
HA peptide stimulation induced vigorous in vitro prolif-
eration of naive clone 4 T cells in the presence of CD4
-
splenocytes from HA- or J-immunized animals (Fig. 4a).
CD4
? splenocytes from J-immunized mice suppressed
peptide-induced clone 4 T cell proliferation more efﬁ-
ciently than CD4
? splenocytes from HA-immunized
mice.
To investigate the effects of co-immunization of the J
peptide with the highly immunogenic HA peptide on HA-
speciﬁc T cell responses in vivo, mice were immunized
once with DC co-loaded with both the HA peptide and
either the J or CDR3 peptide. HA-speciﬁc transgenic clone
4 T cells were adoptively transferred 3 days later. HA-
speciﬁc T cells proliferated vigorously in mice co-immu-
nized with HA and CDR3 peptide (Fig. 4b). Co-immuni-
zation with HA and J resulted in markedly reduced
proliferation of HA-speciﬁc T cells. Depletion of Treg
prior to immunization prevented this inhibition.
Finally, we examined the inﬂuence of J peptide co-
immunization on the initiation of non-TCR-transgenic HA-
speciﬁc T cells in wild-type mice in vivo. Mice were either
immunized with DC loaded with HA and J peptide, or
simultaneously with HA peptide-loaded DC into one leg
and J peptide-loaded DC into the contralateral leg. The
frequency of HA-speciﬁc effector T cells in the draining
LN was increased after co-immunization with both pep-
tides at the same location (Fig. 4c). However, HA-speciﬁc
T cells circulated only when the HA immunization was
anatomically separated from the J peptide. These ﬁndings
Experiment
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B
Fig. 5 Analysis of the Treg
TCR repertoire 1 week after
DC-based immunization against
J and CDR3
het peptide.
a Distribution of TCR Vb
families within CD4
?FoxP3
?
cells as detected by ﬂow
cytometry in the draining lymph
node. b Vb CDR3 length
distribution of isolated
CD4
?CD25
? splenocytes
analyzed by spectratype PCR
with Vb and C speciﬁc primers
Fig. 4 Suppression of HA-speciﬁc T cells by J immunization in vitro
and in vivo. a Ag-dependent suppression of clone 4 T cells in vitro.
Naive, CFSE-labeled CD8
?CD45.1
? clone 4 T cells were incubated
with CD4
- or CD4
? splenocytes from mice immunized with HA or J
peptide in the presence of 10 lM peptide and analyzed after 3 days.
b Ag-dependent suppression of clone 4 T cells in vivo. CD45.1/
CD45.2 heterozygous B10.D2 mice with and without prior depletion
of CD25
? cells were immunized with DC loaded with equal amounts
of HA and either CDR3 or J peptide. 3 days later, CFSE-labeled,
CD45.1
?/?CD8
? clone 4 cells were injected i.v. 1 week after
immunization, CD8
?CD45.2
- and HA peptide/H-2K
d multimer-
positive splenocytes were measured. c Effects of co-immunization
with HA and J peptide on the induction of HA-speciﬁc T cells.
BALB/c mice were immunized with DC loaded with equal concen-
trations of HA and J peptide (co-immunized) or immunized
separately into contralateral hind paws with DC loaded only with
HA or J peptide. HA-speciﬁc T cells were measured after 1 week
b
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123raise the possibility that co-immunization with the J pep-
tide did not affect the induction and initial local expansion
of HA-speciﬁc T cells, but possibly reduce their egress
from the LN despite the downregulation of CD62L.
The Treg TCR repertoire after DC-based peptide
immunization
The differential activity of Treg upon CDR3- and
J-immunization prompted us to search for vaccination-
dependent changes of the Treg TCR repertoire. However,
there was no detectable difference in the distribution of
TCR Vb families in the draining lymph node (Fig. 5a). In
addition, no skewing of the CDR length within Vb tran-
scripts of splenic Treg became apparent after DC-based
immunization (Fig. 5b).
Discussion
Natural Treg have the primary function to control autore-
active T cells in the periphery [32]. Treg may be induced
by organ-speciﬁc self Ag and recognize such Ag through
their TCR [33, 34]. When A20 cells expressing HA as an
artiﬁcial tumor Ag are transferred into mice with HA-
speciﬁc, MHC class II-restricted transgenic T cells,
immunization against HA expands both HA-speciﬁc
effector cells and suppressive cells including Treg [35]. A
dominance of suppression over effector function prevents
therapeutic vaccination efﬁcacy in this model.
In contrast to a predetermined speciﬁcity of Treg
through a transgenic TCR, our experiments are performed
by immunizations with MHC class I-restricted peptides and
in a natural T cell repertoire. The development of a serum-
free protocol to generate ‘‘fully licensed’’ DC in vitro [18]
and the identiﬁcation of an immunogenic CDR3 peptide of
the A20 Id enabled us to interrogate the possible extremes
in Id vaccination, i.e. to analyze responses to a unique
CDR3 peptide versus a FR4/J peptide expressed by many
normal B cells. We identiﬁed transcriptional changes
induced in Treg by an MHC class I-restricted Ag in wild-
type mice and compared these transcriptomes to direct
Treg stimulation enforced through a transgenic TCR [28].
Since the common Treg signature was considerably more
stable after in vivo Treg activation by DC, our experi-
mental system may recapitulate the behavior of Treg in a
natural immune response more accurately. We identiﬁed
upregulation of known Treg effector and cellular interac-
tion molecules, e.g. granzymes, IL-10, TGF-beta [30],
neuropilin [36], CXCR6, CD44, and CD18 [37, 38].
Transcriptional induction of protein dephosphorylation,
DNA methylation, and inhibition of translation initiation
may also be required for suppressive Treg function in an
immunostimulatory environment induced by activated and
licensed DC [18].
Only the J peptide effected a proliferation of Treg iso-
lated from the draining LN despite similar phenotypic and
transcriptional changes in splenic Treg after both immu-
nizations. In addition, TCR repertoire and transcriptome of
Treg were practically indistinguishable after immunization
with immunogenic and nonimmunogenic peptides. There-
fore, the magnitude rather than a particular quality of the
Treg response may determine the outcome of peptide
immunization. Consistent with this hypothesis, the vaccine
formulation may have a critical impact on the immuniza-
tion efﬁcacy, since the Treg-inducing J epitope was origi-
nally identiﬁed as a protective Ag after adenoviral Id
vaccination [26].
The peptides used in this study cannot be recognized by
the MHC class II-restricted TCR of Treg. Therefore, the
J-induced Treg response must involve an indirect mecha-
nism. We assume that the immigrating DCs induce
Ag-speciﬁc T cells in the draining LN. In the case of the
CDR3 and HA peptides, these T cells do not encounter their
antigen on other cells and are able to establish systemic
immunity. In contrast, J-speciﬁc T cells can encounter their
cognate antigen on other resident B cells immediately after
activation, and the resulting release of self Ags from these B
cells could lead to efﬁcient activation of resident Treg.
Treg may suppress speciﬁc T cell responses by inhibit-
ing their ampliﬁcation through proliferation [39] and acting
directly at the site of T cell activation [40]. Both levels of
inhibition may be operational in our experimental system:
J peptide-activated Treg exerted systemic inhibition of
Ag-speciﬁc T cell proliferation. However, we also ﬁnd
preliminary evidence for an impaired exit of activated
CD8
? cells from the draining LN after co-immunization
with the J peptide.
In summary, our data identify Treg-mediated peripheral
tolerance as a mechanism controlling the speciﬁcity of
vaccination-induced anti-Id cellular immunity. In this
model, a peptide shared between neoplastic and normal
cells can suppress effector T cell activity against unique
tumor-derived and microbial epitopes. The absence of Treg
in in vitro stimulation cultures of isolated CD8
? T cells
may also permit recognition of FR peptides [41]; however,
this T cell activity would be expected to be suppressed in
vivo by Treg. Treg activity may also explain the observed
speciﬁcity of vaccination-induced T cell responses for
CDR and hypermutated epitopes in lymphoma patients [3,
15, 16] and the dominant role of CDR epitopes in Id-
directed immunosurveillance despite better HLA-binding
capacity of FR peptides [14]. An individual idiotype’s net
immunogenicity is presumably dependent on the balance
between individual immunogenic epitopes and the sup-
pressive effects of conserved peptides. This critical balance
58 Cancer Immunol Immunother (2011) 60:49–60
123could offer a plausible, albeit difﬁcult to prove, explanation
for lack of cellular and perhaps humoral immune responses
as observed in individual patients in clinical Id vaccination
trials [2–7, 16].
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